Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 20.72 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; microcrystalline cellulose; sodium carbonate; purified talc; povidone; methionine; mannitol; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium carbonate; purified talc; povidone; methionine; microcrystalline cellulose; crospovidone; mannitol; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rocuronium bromide, quantity: 100 mg - injection, solution - excipient ingredients: acetic acid; sodium hydroxide; sodium chloride; water for injections; sodium acetate trihydrate - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age.. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. rocuronium is also indicated as an adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rocuronium bromide, quantity: 50 mg - injection, solution - excipient ingredients: sodium hydroxide; acetic acid; water for injections; sodium acetate trihydrate; sodium chloride - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age.. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. rocuronium is also indicated as an adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium trihydrate, quantity: 86.8 mg - tablet, film coated - excipient ingredients: povidone; crospovidone; sodium carbonate; magnesium stearate; microcrystalline cellulose; glycerol dibehenate; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. ,atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium trihydrate, quantity: 86.8 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glycerol dibehenate; magnesium stearate; crospovidone; povidone; sodium carbonate; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. ,atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - gemfibrozil, quantity: 600 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; pregelatinised maize starch; calcium stearate; microcrystalline cellulose; polysorbate 80; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - gemfibrozil is indicated as an adjunct to diet and other therapeutic measures for the following: * severe hypertriglyceridaemia (types iv and v) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. * dyslipidaemia associated with diabetes. * reduction of risk of coronary heart disease in patients with type iia and iib hypercholesterolaemia. * because of potential toxicity such as malignancy, gall bladder disease, abdominal pain leading to appendicectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with the chemically and pharmacologically related drug clofibrate, the potential benefits of gemfibrozil in treating type iia patients with elevations of ldl choleserol only is not likely to outweigh the risks. in a subgroup analysis of patients in the helsinki heart study with above median hdl cholesterol values at baseline (greater than 1.2mmol/l), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. note: gemfibrozil is indicated when exercise, weight loss and specific dietary or other non-drug measures such as limiting alcohol intake have failed. other medical disorders such as hypothyroidism and diabetes should be controlled as much as possible. periodic determinations of serum lipids should be obtained during treatment with gemfibrozil. the drug should be withdrawn or additionals therapy instituted if the lipid response is deemed inadequate after three months.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - mometasone furoate, quantity: 1 mg/g - lotion - excipient ingredients: monobasic sodium phosphate; phosphoric acid; propylene glycol; hyprolose; isopropyl alcohol; purified water - short-term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, such as psoriasis and atopic dermatitis. the lotion is also suitable for short-term use for scalp psoriasis and seborrhoeic dermatitis.